NE

Newpathmolecular

2 known investors

newpathmolecular.com ↗

New Path Molecular develops drug conjugates targeting phosphatidylserine on cancer cell membranes to treat solid tumors with reduced toxicity to healthy tissue. The company's lead program, PDC-1, is designed to treat colorectal and pancreatic cancer and is advancing toward clinical candidate selection.

Investors · 2

DE

Deepbridge CapitalChester

OX

Oxford Investment Opportunity Network (OION)Oxford · $190K – $2.5M